Insmed (INSM) Capital Expenditures Growth (1y) (2012 - 2026)
Powered by 
Analysis
Insmed (INSM) Capital Expenditures Growth (1y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 39.02% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 30.84% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -22.99% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 9.68% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 1,133.33% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 142.64% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 53.76% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -73.62% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -106.89% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -73.62% |
| Mar 31, 2026 | 134.23% |
| Dec 31, 2025 | 144.96% |
| Sep 30, 2025 | -92.16% |
| Jun 30, 2025 | 216.41% |
| Mar 31, 2025 | -317.31% |
| Dec 31, 2024 | 113.70% |
| Sep 30, 2024 | 257.72% |
| Jun 30, 2024 | -768.13% |
| Mar 31, 2024 | -10.55% |
| Dec 31, 2023 | -74.07% |
| Sep 30, 2023 | 443.86% |
| Jun 30, 2023 | -67.00% |
| Mar 31, 2023 | -16.82% |
| Dec 31, 2022 | 255.13% |
| Sep 30, 2022 | -53.96% |
| Jun 30, 2022 | 219.57% |
| Mar 31, 2022 | -68.13% |
| Dec 31, 2021 | 260.69% |
| Sep 30, 2021 | -318.07% |